ABSTRACT
INTRODUCTION
Multiple myeloma (MM) is a clonal B-cell malignancy affecting both the immune system and bone destruction. It is the second most frequent hematological malignancy inflicting 40,000 people in the USA, with a 5-year survival of less than 20% (1) (2) (3) . Therefore, new therapeutic modalities are needed for this disease.
Arsenic trioxide (ATO), like all-trans retinoic acid (ATRA) is a potent drug in the treatment of acute promyelocytic leukemia (APL) (4) and like ATRA has been shown to induce differentiation and apoptosis of APL cells, in vitro and in vivo in animal models (5) . Most importantly, ATO is very effective in the treatment of APL patients with very little toxicity (6) .
ATO is a potent inducer of apoptosis in a number of other cell types such as AML (7), gastric cancer (8) , neuroblastoma (9) (10) and in MC/CAR cells (11) . The exact mechanism of ATOinduced apoptosis is not yet clear. Several mechanisms were proposed to explain ATO-induced differentiation and apoptosis of APL cells. One mechanism, similar to ATRA, involves down regulation of the PML protein through binding to the RARα portion of the PML-RARα fusion protein, the product of the t(15:17) translocation. However, since ATO is effective in APL patients resistant to ATRA (12) (13) , and is cytotoxic to cells lacking the PML-RARα fusion protein, other mechanisms of action were also attributed to ATO, in cells lacking the t(15:17) translocation. These mechanisms include mitochondrial damage (5, (14) (15) , activation of histone deacetylase (16) , blocking of cells in G1 by induction of p21in MC-CAR cells (11) and blocking of cell cycle in G2/M in U937 cells (17) . Activation of caspases such as caspase-3 (10, 18) , caspase 9 (19) and caspase 8 (20) were also reported for ATO-induced apoptosis.
TNF-related, apoptosis inducing ligand (APO2/TRAIL) belongs to the large family of TNF-like signal-inducing proteins, and their corresponding receptors, belong to the For personal use only. on . by guest www.bloodjournal.org From 4 large family of TNF-like signal transduction receptor proteins. APO2/TRAIL induces a death signal following binding to the R1 or R2, APO2/TRAIL-receptors (21) (22) (23) (24) (25) . Normal cells escape APO2/TRAIL-induced apoptosis by virtue of co-expressing decoy receptor molecules such as R3 or R4, which are capable of binding of APO2/TRAIL but lack the intracellular death domains which transmits down stream cell death signals through activation of caspase 8 (24) . Tumor cells generally do not express these decoy receptor molecules (26) (27) (28) . Other mechanisms for APO2/TRAIL resistance include mutations in caspase-8, the primary caspase involved in APO2/TRAIL death signaling upstream from caspase-3 (29) (30) (31) .
We have previously shown that APO2/TRAIL and Adenovirus-mediated delivery of p53 (Ad-p53) are potent inducers of apoptosis in myeloma cells (32) (33) (34) . More recently, we have shown that Ad-p53 synergizes with APO2/TRAIL in the induction of apoptosis in myeloma cells through upregulation of R1 and R2 APO2/TRAIL receptors (35) (36) . Others have recently shown that treatment with various chemotherapeutic drugs (37) (38) (39) or ionizing radiation also results in the induction of APO2/TRAIL receptors and APO2/TRAIL decoy receptors (40) . In addition, APO2/TRAIL has been shown to exert an anti tumor effect in vivo in different xenograft models of cancer and exhibited very limited toxicity in monkeys (41) .
In this study we conducted a detailed analysis of the pathways of ATO-induced apoptosis in myeloma cells with different p53 status. We describe 2 distinct pathways for ATOinduced apoptosis in terms of the effect on cell cycle and involvement of initiator caspases, depending of p53 status. In addition, we report here, for the first time that ATO synergizes with APO2/TRAIL in the induction of apoptosis in myeloma cells through upregulation of R1 and R2 APO2/TRAIL receptors. Preliminary results from this work were presented at the 43 rd Annual
Meeting of the American Society of Hematology, in Orlando (December, 2001) (42) .
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METHODOLOGY
Cell lines, cell culture and induction of apoptosis by arsenic trioxide
The list of all myeloma cell lines used in this study, their source and p53 status is depicted in Table 1 . Cells (4x10 5 /ml) were cultured in 1ml of RPMI 1640 medium plus 15% fetal calf serum (FCS-medium) (GIBCO, Grand Island, NY), in a 24-well plate in a CO 2 incubator.
Arsenic trioxide (ATO, Trisenox, Cell Therapeutics Inc., Seattle, WA) was added at concentrations of 0-10 µM and cultures were harvested after 24 and 28 hours and were tested for apoptosis by the Annexin V method (see below)
2. Cell culture and induction of apoptosis by APO2/TRAIL Cells (4x10 5 /ml) were cultured in 1ml of FCS-medium, in a 24-well plate. Purified, recombinant, native-sequence, trimeric, human APO2/TRAIL (Genentech Inc., South San
Francisco, CA), was added at 0-100ng/ml and wells were harvested after 24 and 48 hours of treatment and tested for apoptosis as described below. For combination studies of ATO and APO2/TRAIL, 0-10µM ATO was added to wells containing 0-100ng/ml of APO2/ TRAIL. 
Analysis of cell cycle
Cells (4x10 5 /ml) were cultured in 1ml of FCS-medium, in a 24-well plate. The effect of ATO on the cell cycle was determined by staining of myeloma cells with propidium iodide as described Fig 1A. We observed a time and dose dependent apoptosis between 1 to 10 µM of ATO with apoptosis of >85% observed after 48 hours of treatment with 10 µM of ATO in U266 and 8226 cells. The kinetics and extent of apoptosis for these myeloma cells were similar to the extent of apoptosis observed for the NB4, used here as a reference for ATO-sensitive target cells (Fig. 1A) . In contrast, HS-Sultan, IM9 and MC-CAR cells (all express w.t. p53) were less sensitive to ATO at all time points tested and maximal apoptosis was only 35%, following 48 hours exposure to 10ìM of ATO (Fig. 1B) . 
Downstream caspases involved in ATO-induced apoptosis in cells expressing w.t or mutated p53
We then compared the effect of ATO on caspase activation in myeloma cells expressing w.t. p53 or mutated p53. This was accomplished by 3 different methods: by using caspase-specific inhibitory peptides; by employing fluorescence tagged caspase specific substrate peptides and by Western immunoblotting. We first assayed caspase activation by caspase specific blocking peptides.
U266 cells (mutated p53) and HS-Sultan cells (w.t. p53) were cultured for 48 hours with 7.5 µM of ATO with or without 2ìM of the caspase specific blocking peptide, or control peptide (FA-FMK) and apoptosis was estimated by the annexin V method. The results obtained with caspase blocking peptides are depicted in Figure 5 . Ten different caspase blocking peptides were employed. Caspase 3 and the pan caspase blocking peptide, Z-VAD substantially blocked ATO-induced apoptosis in both cell lines. In U266 cells caspase 8 and caspase 10 blocking peptide completely blocked apoptosis, whereas, caspase 9 blocking peptide only partially blocked apoptosis (25%) in these cells. In contrast to U266 cells, caspase 9 inhibitor completely blocked apoptosis in HS-Sultan cells, whereas, caspase 8 and 10 blocking peptide had minimal effect (Fig. 5) . Interestingly, WEHD (caspase 5 inhibitor) and VEID (caspase 6 inhibitor) partially blocked apoptosis in U266 cells but were ineffective in blocking of apoptosis in HS-Sultan cells. Inhibitors of caspase 1, 2 were practically ineffective in blocking apoptosis in both cell lines (Fig. 5) . Non-specific toxicity of the control peptide (CP) was low and toxicity of the blocking peptide was <5% (results not shown). These results, taken together suggest (Fig. 6 ).
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ATO-INDUCED CASPASE ACTIVATION AND APOPTOSIS
0H
16H 24H 48H 
Synergy between ATO and APO2/TRAIL in the induction of apoptosis
It has been reported that certain chemotherapeutic drugs induce APO2/TRAIL receptors and thereby can potentially engage both, the intrinsic and the extrinsic apoptotic pathways. We hypothesized that treatment with ATO may also result in induction of APO2/TRAIL receptors. We therefore tested the combined effect of ATO (0-10ìM) and APO2/TRAIL (0-100ng/ml) in myeloma for 48 hours resulted with 43% and 57% apoptosis, respectively, whereas the combination of the 2 drugs resulted with 97% apoptosis. Similar results were obtained for U266 where apoptosis with APO2/TRAIL and ATO resulted with a maximum of 97% apoptosis with both drugs, compared to a maximum of 40% and 59% with APO2/TRAIL or ATO alone, respectively, at 10ìM of ATO and 100ng/ml of APO2/TRAIL (Fig. 9) . These results clearly indicated that in cell lines expressing w.t p53, which are partially resistant to ATO, the combination of ATO and APO2/TRAIL results with a synergy between the 2 drugs. . We tested for synergy using two, one-sided, two sample t-tests to determine whether apoptosis, as measured by the percent of cells positive for Annexin V, was lower in cells treated with a full dose of a single agent (APO2/TRAIL 100 ng/ml, ATO 10 µM)
than in cells treated with a 50:50 combinations (APO2/TRAIL 50 ng/ml + ATO 5µM) (56).
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Tests were conducted at an alpha of 0.025 level of significance and the maximum of the two one-sided tests is reported as the P-value for the overall test. The results indicate clear synergy of the combination of 5µM ATO and 50ng/ml of APO2/TRAIL compared to 10µM of ATO and 100ng/ml of APO2/TRAIL, as single drugs, in all 4 cell lines tested. The P values were >0.0001, 0.0005, 0.0008 and 0.001 for HS-Sultan, IM9, ARP-1 and U266, respectively.
In our studies APO2/TRAIL was present throughout the experiment. However, we have evidence that the increase in the expression of R1 and R2 TRAIL receptors is not permanent and a substantial internalization of the receptors occurs 36-48 hours after removal of TRAIL (Gazitt, unpublished results). (Fig. 11A) and following 24 hours of treatment with 4µM of ATO (Fig. 11B) . Before treatment, both R1 and R2 APO2/TRAIL receptors were expressed on the surface of IM9 cells with relatively low expression of R3 and R4 APO2/TRAIL decoy receptors. However, treatment with ATO resulted with enhanced expression of R1/R2 APO2/TRAIL receptors from 46% to 82% and from 21% to 58% for R1 and R2 TRAIL receptors, respectively.
Concomitant with the observed increase in the expression of R1 and R2 TRAIL receptors, we observed a decrease in the expression of R3/R4 decoy receptors, from 22% and 28% to 3 % and 2% for R3 and R4 TRAIL decoy receptors, respectively. We conclude that the synergy between ATO and APO2/TRAIL is indeed the result of early modulation of APO2/TRAIL receptors. To test whether freshly isolated myeloma cells behave as myeloma cell lines, we isolated (CD38+ CD45-) myeloma cells from the bone marrow of 6 MM patients by flow-sorting and myeloma cells with >95% purity were obtained (33) . Freshly isolated myeloma cells were cultured for 2 days with 4 µM of ATO, 100ng/ml of APO2/TRAIL, or both and apoptosis was scored after 24 and 48 hours. The results are depicted in Table 2 Concomitant with G1 arrest, we observed substantial upregulation of p21 in these cells which explain the small increase in G1 arrest. These results, explain the apparent contradictory results In the presence of functional p53, ATO acts like DNA damaging agent (e.g. UV and ionizing radiation), most likely inducing DNA breaks which trigger p53-dependent DNA repair apparatus involving upregulation of gadd45, p21 and blocking of G1 cyclins followed by G1 arrest and eventually leading to differentiation and/or apoptosis (5, (47) (48) . Apoptosis in cells with functional p53 could also be induced by ATO as a result of p53-dependent trans activation of the apoptosis inducing protein, p53AIP1 leading to mitochondrial damage and apoptosis via the intrinsic mitochondrial pathway (49) . This apoptotic pathway could be activated if one assumes that ATO, directly or indirectly can induce phosphorylation of ser-46 on the p53 molecule (49) . This possibility is now under investigation in our laboratory. On the other hand, in the absence of functional p53 and G1 arrest, DNA damage can result in a G2 arrest independent of p53 but involving other DNA-damage sensing proteins, such as Atm and Atr through a down stream activation of Chk1 and Chk2 kinases which phosphorylate the Cdc25 phosphatase and thus blocking Cdc25-regulated dephosphorylation of Cdc2. This can lead to blocking of the formation of the mitotic cyclin B/Cdc2 complex, effectively blocking cells in G2 (50) . Preliminary studies in our laboratory suggest that a p53-independent (20) . If the difference between these 2 cell lines is the status of p53 than our results explain the seemingly conflicting reports by these 2 groups for caspase activation by ATO. Caspase 8 and 10 are the primary caspases involved in the well characterized extrinsic apoptosis pathways attributed to the fasL and TRAIL (24, (51) (52) , whereas caspase 9 is the primary caspase involved in the intrinsic mitochondrial pathway (53) . In rare cases the 2 apoptotic pathways could be linked through activation by caspase 8 of the proapoptotic protein, Bid resulting in its translocation to the mitochondria and apoptosis via mitochondrial damage (54) . It is possible that ATO might be involved in triggering both apoptotic pathways since results from our lab clearly suggest that depolarization of mitochondrial membrane potential are likely to be clinically relevant and that these 2 drugs might work in a similar way in vivo. In this regard, it is important to note that in APL patients, treated with 0.15 mg/kg/day of ATO, a [C]max of 1-2ìM of ATO in the plasma was documented (4, 6). However, multiple myeloma patients, receive between 0.25 to 0.4 mg/kg/day of ATO. Therefore, the [C] max of ATO in these patients is expected to be much higher than in APL patients and well within the effective doses of 3-6 µM used in our study. Finally, it is important to mention that ATO has been used in myeloma patients in phase I-II clinical trials as a single agent, or in combination with ascorbic acid, or in combination with thalidomide. Given the low toxicity of TRAIL and ATO and given the synergy we observed between the 2 drugs, our results justify the use of the combination of these 2 drugs for the treatment of MM patients. 
